Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma
Status:
Completed
Trial end date:
2013-09-19
Target enrollment:
Participant gender:
Summary
RATIONALE: Thalidomide may stop the growth of multiple myeloma by stopping blood flow to the
tumor. It is not yet known whether combining thalidomide with prednisone and giving them
after autologous stem cell transplantation may be effective in treating multiple myeloma.
PURPOSE: This randomized phase III trial is studying thalidomide and prednisone to see how
well they work compared to observation in treating patients who have undergone stem cell
transplantation for multiple myeloma.
Phase:
Phase 3
Details
Lead Sponsor:
NCIC Clinical Trials Group
Collaborators:
Eastern Cooperative Oncology Group National Cancer Institute (NCI)